The study involves a crossover design, which means participants will receive different versions of the medication at different times during the trial. This approach allows for a comparison of how the body processes each version. Additionally, the study will evaluate the food effect, which refers to how eating meals might change the way the medicine is absorbed into the bloodstream. All participants will take the medication through oral use, meaning the tablets are swallowed by mouth.

The purpose of the study is to test whether the experimental treatment is effective and safe in reducing severe health problems that can occur after surgery. The study focuses on patients who have an unfavorable inflammatory profile, meaning their body shows signs of higher inflammation levels before surgery. The treatment aims to target this inflammation to help prevent complications that might develop within 90 days and up to one year after the operation.

Patients in the study will receive acetylsalicylic acid at a dose of 100 mg daily for up to 11 months and ketorolac trometamol at a dose of 30 mg/ml for one day. The study will monitor how well the treatment works and whether it causes any unwanted effects. Participants must have confirmed cancer diagnosis, be scheduled for surgery intended to cure the cancer, and have certain blood test results showing adequate organ function. The study will track patients’ recovery and any health problems that may occur following their cancer surgery.

The purpose of the study is to explore how these medications can modify the immune system’s response during inflammation. Participants will receive one of the medications or a placebo, and their immune responses will be monitored. The study will involve repeated exposure to a substance called lipopolysaccharide (LPS), which is used to trigger an inflammatory response in the body. This will help researchers understand how the medications affect the immune system over time.

Throughout the study, participants will undergo various tests and assessments to measure changes in their immune response. These tests will include monitoring levels of certain proteins and substances in the blood that are associated with inflammation. The study aims to provide valuable insights into how these medications can potentially be used to manage inflammatory conditions in the future.

The purpose of this research is to determine if the new imaging tracer can work as well as or better than the current standard method in detecting and evaluating inflammatory conditions. The study will look at how well each tracer can identify the source of unexplained fever and inflammation, assess the extent of IgG4-related disease (a condition that can affect multiple organs), and distinguish between inflammatory and mechanical back pain in patients with spine problems.

During the study, participants will receive an intravenous injection of the imaging tracer before undergoing the PET/CT scan. Some participants may need to have two scans, particularly those with spine conditions who will be evaluated before and after three months of treatment. The maximum amount of tracer used for each scan will be 100 MBq, with a total maximum dose of 550 MBq over the entire study period.

The purpose of the study is to determine if colchicine treatment can reduce the progression of moderate aortic valve stenosis by decreasing inflammation and calcium buildup in the heart valve. Participants in this study will receive either colchicine tablets or placebo tablets for approximately 24 months.

The study will use various imaging techniques to monitor changes in the heart valve over time, including computed tomography scans to measure calcium buildup, echocardiography (ultrasound of the heart) to assess blood flow through the valve, and positron emission tomography to evaluate valve activity. The study is designed so that neither the participants nor the researchers will know who is receiving which treatment.

The purpose of the study is to determine if stopping glucocorticoid treatment quickly is as safe and effective as slowly reducing the dose. Participants will be randomly assigned to one of the two groups. Some participants will receive a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of up to 28 days, during which participants will be monitored for any health changes, including the need for additional treatment or any serious health events.

Throughout the study, participants’ overall health and any symptoms they experience will be closely observed. This includes monitoring for signs of adrenal insufficiency, a condition where the body does not produce enough of certain hormones after stopping steroid treatment. The study aims to provide valuable information on the best way to discontinue glucocorticoid therapy in patients with inflammatory conditions, ensuring their safety and well-being.

The purpose of the study is to observe and describe how the tracer behaves in the body and how it highlights different areas affected by the diseases. The study will involve a single injection of the tracer, followed by a PET/CT scan to capture images of the affected areas. This will help researchers understand the intensity and location of the disease activity in the body.

The study will take place over a period of time, with participants undergoing the imaging process at the start of the study. The information gathered from these images will be used to better understand the diseases and potentially improve future treatments. The study aims to provide valuable insights into how these diseases affect the body and how they can be better managed in the future.